Edith Cowan University

Research Online
Research outputs 2014 to 2021
2016

Finding chemopreventatives to reduce amyloid beta in yeast
Ian Macreadie
Costa Arvanitis
Prashant Bharadwaj
Edith Cowan University

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Neurology Commons, Neurosciences Commons, and the Preventive Medicine Commons
10.4103/1673-5374.177729
Macreadie, I. G., Arvanitis, C., & Bharadwaj, P. (2016). Finding chemopreventatives to reduce amyloid beta in yeast.
Neural Regeneration Research, 11(2), 244.
https://doi.org/10.4103/1673-5374.177729
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/1851

NEURAL REGENERATION RESEARCH
February 2016,Volume 11,Issue 2

www.nrronline.org

PERSPECTIVE

Finding chemopreventatives to reduce
amyloid beta in yeast
Alzheimer’s disease (AD) is the most common form of age-related dementia with the latest report (WorldAlzheimerReport,
2015) showing 46.8 million people are currently affected by
dementia. That number is expected to double every 20 years
unless there is effective therapeutic intervention.
The 42 amino acid peptide known as amyloid beta (or Aβ)
has been implicated as one of the main causative agents of AD
after its discovery in plaques in 1985 (Masters et al., 1985). Since
then evidence has accumulated to support the association between AD and Aβ.
Amyloid beta in AD:
Findings

Reference

Mutations in amyloid beta lead to early
onset of the disease
Scheuner et al., 1996
Mutations leading to less production
of amyloid beta appear protective
Amyloid beta is toxic to neuronal cells

Reviewed in Porzoor and
Macreadie, 2013

Isolation of amyloid beta from senile
plaques in AD brains

Masters et al., 1985

Jonsson et al., 2012

Reviewed in Porzoor et al.,
2014
Accumulation of soluble amyloid beta McLean et al., 1999
in brain correlates to severity of disease

However, progress to find a cure for AD has been very slow, due
to lack of reliable models and a lack of understanding about
what role Aβ plays in AD (reviewed in Moosavi et al., 2015).
For a period, funding agencies including the Alzheimer’s
Association and the Alzheimer’s Drug Foundation were turning away from projects focused on Aβ. To be fair, part of the
rationale was probably to diversify their portfolio, but certainly
many have questioned the approaches used in Aβ research.
Convincing evidence of Aβ being the cause of AD has been
sought through treatments with therapeutic antibodies that bind
and remove Aβ. Such treatments include the humanized monoclonal antibodies crenezumab (a homologue of bapineuzamab).
Results in clinical trials with bapineuzumab were initially promising and showed clearance of brain amyloid and the lowering of
phosphorylated tau protein in the cerebrospinal fluid, however,
people did not recover from AD. The failure to cure AD (Panza et
al., 2012) led many to doubt that Aβ should be the prime target
for the treatment of AD, resulting in a backlash against research
on Aβ as a drug target (e.g., see Hyman and Sorger, 2015). The
recent antibody trial is showing some promise, although it did
not meet the desired end points (Underwood, 2015).
Two non-exclusive hypotheses for the failures are poor bloodbrain barrier penetration (0.1%) and treatment of patients who
progressed too far to recover from the disease. Now the tide may
turn. A major trial, using people who have no disease but who
have biomarkers indicating a likely progression to AD, is addressing the question of whether therapeutic antibodies against Aβ
might prevent AD. The early indications are that therapeutic antibodies that clear Aβ can indeed prevent or delay development
of AD. Aβ appears like it will be in vogue as a target once again!
Therapeutic antibodies are magic bullets for acute diseases
like cancer. They are very expensive but affordable in a wealthy
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society over the relatively short duration for the treatment of
acute diseases. But therapeutic antibodies are not the answer
for prevention of a chronic disease like AD. They are simply not
affordable, and they appear impractical for extended use. They
are important in establishing that Aβ is a valid target for therapy but frequent injections and huge on-going cost means that
long term use as a therapy is not viable.
While a description of all the metabolic pathways of Aβ production and clearance is beyond the scope of this perspective,
(for a review see Zhang et al., 2011), the well documented beneficial effects of statins can be mentioned. Studies have found
up to a 70 % decreased risk of AD in people taking statins and
reduced production of Aβ. The stains, originally used as cholesterol inhibitors are now being used to manage neurodegenerative disorders such as vascular dementia and AD. In a research
article focusing on effects of Simvastatin in AD, researchers
demonstrated a differential dose-dependent effect with Simvastatin on hypoxia inducible factor 1α (HIF-1α) and amyloid
precursor protein cleaving enzyme (BACE) in cultured AD
cytoplasmic hybrid cells (cybrid cells). These Cybrid cells are
being used in research to study dysfunctional mitochondria in
AD pathogenesis (Jeong et al., 2015).
There is growing interest in naturally derived compounds
as chemopreventatives to remove Aβ. Such compounds
should be taken conveniently, which means it is best if they
can be ingested. Epidemiology suggests there are many compounds in existing foods that may be useful for chemoprevention of AD (Pandey and Risvi, 2009). Since we have reasonable ideas about the molecular basis of Aβ, it is important
that we incorporate these ideas into rational screening for AD
chemopreventatives.
What do we know about Aβ and what it does? We know that
Aβ accumulates in brains with age. In yeast we have found that
young cells, that are newly budded, remove Aβ. Slightly older
cells also clear it. But the oldest cells, “grand mothers” retain the
Aβ. We know this from in vitro studies where the Aβ is fused to
green fluorescent protein (GFP) (see Figure 1). The older cells
are readily recognized by the presence of multiple bud scars: one
bud scar is left for every cell budded off. In Figure 1, isogenic
cells from the same parent can be observed: the older cells with
multiple bud scars (stained with calcofluor) have accumulated
Aβ and exhibit green fluorescence. It can also be observed that
the older cells pass the green fluorescent fusion protein to their
progeny, and for a brief time the bud is fluorescent, but it rapidly disappears due to increased autophagy in the young cell.
How do we apply this knowledge? We can screen for compounds that reduce the Aβ related pathology in a cell population.
Our detailed methods of doing this are recently published (Porzoor and Macreadie, 2015). Useful compounds (a) increase clearance of Aβ, or (b) reduce Aβ induced toxicity. Such compounds
may be useful as chemopreventatives that reduce the level of Aβ,
and they may have broader benefits for other age-related protein
misfolding diseases. Laterpiridine is a compound that has some
history as an AD drug and yeast screening studies show that it
increases turnover of Aβ (Bharadwaj et al., 2012). It has also been
shown that pure components of green tea, epigallocatechin gallate (EGCG), and salvianolic acid (from the traditional Chinese
herb, Danshen) lead to reduced levels of Aβ (Porzoor et al., 2015).
Interestingly in vitro studies also show that EGCG and salvianolic
acid block fibril formation, suggesting the direct interaction between amyloid beta and these compounds (Porzoor et al., 2015).
To explain the in vivo results it would appear that such binding
targets the Aβ-salvianolic acid complex, or Aβ-EGCG complex
for degradation. An alternate explanation is that salvianolic acid
or EGCG might trigger autophagy independently. Either way, the
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Figure 1 Amyloid beta persists in older yeast cells.
(A) Two pairs of yeast cells that are budding. (B) Cells producing amyloid beta fused to green fluorescent protein (GFP) and the fluorescence is
readily observed in older cells as punctate patches. (C) Bud scars that are stained with calcofluor. The young cells receive the fluorescent amyloid
beta but rapidly remove it (not shown).

removal of Aβ is the desired outcome.
Aβ is cytotoxic as an oligomeric species, and this characteristic
also lends itself to screening. Such screening can be performed
using the exogenous addition of chemically-synthesised Aβ.
However, recently doubts have been created about the preparation of such peptide (Porzoor et al., 2014). The more common
hexafluoroisopropanol method results in toxic peptide, but an
ammonium hydroxide preparation results in Aβ that stimulates
growth. Which preparation is biologically relevant? Certainly
cellular toxicity is widely looked at, but stimulation of growth
may be relevant, since neuronal cells are terminally differentiated and do not divide, but in AD many neuronal cells are found
to have entered a cell division cells that has led to their death!
The more convenient assay is to look for oligomerisation in the
Aβ fused to green fluorescent protein (GFP). Monomeric Aβ
fused to GFP will exhibit full fluorescence levels, but the dimeric
species is not expected to fluoresce. Therefore increasing green
fluorescence should also be a good outcome. Indeed this is the
basis of assays developed in E. coli, where all fusion protein is
non-fluorescent, but fluorescent in the presence of oligomerisation inhibitors (Park et al., 2011).
The ability of yeast to be used as a tool for screening anti amyloidogenic compounds is a useful and unique contribution. It
can be adapted to high throughput use, it informs about compounds that are bioavailable, and it requires no Aβ preparation.
In a world that seeks new ways to lower Aβ, the yeast assays
should be valuable additions to moving forward.
AD chemopreventatives are an economical approach to
protect the future aging population. The solution will not be a
single compound but is likely to comprise pharmaceuticals and
nutraceuticals that not only target Aβ but improve overall cell
robustness.
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